announced today it has received commercial acceptance of its automated IMA tube filling range. The line will be put to use immediately for the commercial manufacture of a sterile ophthalmic ointment lately accepted by the FDA. The IMA line has a capacity of 30,000 tubes per change with tube size diameters ranging 10 to 60 mm with volumes which range from 1 to 50 grams. The range will be used to fill up sterile gels primarily, creams and ointments. AMP’s innovative process design expertise was a key factor in attaining these approvals. These approvals open up a new door for us, as we find nasal and otic medication items pushed into sterile filling along with ophthalmics which have always been packaged sterile, said Valdes..A total of 42 of the 128 individuals discontinued glucocorticoids totally. Safety Table 3Table 3Adverse Events in both Trials. Summarizes adverse events that occurred through the two trials. No affected person in trial 1 discontinued the analysis because of an adverse event; in the withdrawal stage of trial 2, three patients in the placebo group withdrew because of a serious adverse event . Another three individuals in the placebo group withdrew due to nonserious adverse events . In trial 1, two serious adverse events were reported in each combined group.